All Type of News
‘Jardiance’ entering insurance benefit will expand SGLT-2 inhibitor market with Forxiga
Followed by AstraZeneca’s Forxiga and Astellas’s Suglat, Boehringer Ingelheim’s Jardiance entered the health insurance benefit door for the third time as a SGLT-2 inhibitor.
The last year’s prescriptions of Forxiga, ...
50 pharmaceutical distribution companies exceeded KRW 100 billion annual sales
It was observed there are about 50 pharmaceutical distribution companies which made more than 100 billion annual sales last year.
Moreover, their size of business has gotten bigger, but their profitability was analyz...
Lysozyme chloride & pronase single drugs to be suspended and collected
The Ministry of Food and Drug Safety(Minister Moon-gi Sohn) announced orders to suspend sales of ‘lysozyme chloride’ single drugs and ‘pronase’ single drug that are used to treat patients having difficulties in spitti...
Will Opdivo bring new turning point in treating lung cancer?
Opdivo has attracted interests if it could bring a new paradigm in treating lung cancer through acquiring the first domestic approval as a non-small cell lung cancer immune antibody.
Ono Pharma(CEO Ito Kynihiko) and ...
“Stop distorted rumors,” regarding olmesartan issue
Pharmaceutical companies related to ‘olmesartan’ which is prohibited in health insurance benefit are under a state of emergency.
According to the pharmaceutical industry on the 15th, a number of patients started to r...
‘Eraser in mind,’ dementia costs more than 1 trillion medical expenses
It was observed occurrence of dementia starts get high in the 70s, and 3 of 10 people in the 90s or higher are treated for dementia. For the past 5 years, the number of treated patients and the medical expenses were i...
“We welcome decision to take corrective order on Merial refusing to animal drugs”
The Korean Pharmaceutical Association(President Chan-hui Jo, KPA) expressed an opinion to welcome the fact Merial South Korea, which rejected to supply animal drugs to pet pharmacies, received corrective orders from t...
Multinational pharmaceutical companies’ average annual wage of KRW 73 million
It was observed the average annual wage of multinational pharmaceutical companies’ employees was KRW 73 million, and employees at GlaxoSmithKline, UCB Korea and Sanofi receive more than KRW 100 million annually.
Acc...
Multinational companies focusing on non-benefit products had high sales management expenses
Last year, multinational pharmaceutical companies were observed to reduce their sales management expenses.
According to the sales management expenses based on 31 multinational companies’ 2015 audit reports on the 15...
Jardiance with KRW 703, Sovaldi with KRW 270,656
18 new products, such as a chronic hepatitis C therapy Sovaldi Tab(sofosbuvir), will be registered for the insurance benefit on the 1st of the next month.
There are 9 products each, products with price negotiated bet...
